[go: up one dir, main page]

BR9908518A - Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios - Google Patents

Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios

Info

Publication number
BR9908518A
BR9908518A BR9908518-6A BR9908518A BR9908518A BR 9908518 A BR9908518 A BR 9908518A BR 9908518 A BR9908518 A BR 9908518A BR 9908518 A BR9908518 A BR 9908518A
Authority
BR
Brazil
Prior art keywords
treatment
gene therapy
promote
functional analog
therapeutic
Prior art date
Application number
BR9908518-6A
Other languages
English (en)
Inventor
Herbert Schwarz
Joachim Langstein
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of BR9908518A publication Critical patent/BR9908518A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DO FATOR DE CRESCIMENTO DE MONóCITOS CD137 OU DE UM ANáLOGO FUNCIONAL DO MESMO, PROCESSOS IN VITRO PARA PROMOVER A PROLIFERAçãO DE MONóCITOS PERIFéRICOS, PARA O TRATAMENTO REGENERATIVO DE PACIENTES DE QUIMIOTERAPIA OU DE TERAPIA COM RADIAçãO, E PARA PROMOVER A DEFESA IMUNOLóGICA NãO-ESPECìFICA ENDóGENA, UTILIZAçãO DE UMA SEQuêNCIA DE NUCLEOTìDEOS QUE CODIFICA PARA CD137 OU UM ANáLOGO FUNCIONAL DO MESMO, COMPOSIçãO DE TERAPIA DE GENES, E, PROCESSO DE TERAPIA DE GENES PARA O TRATAMENTO DE UM DOS DISTúRBIOS". A invenção refere-se à utilização de fator de crescimento de monócitos CD137 ou de um análogo funcional do mesmo para produzir um medicamento para promover a proliferação de monócitos periféricos de um mamífero. A invenção refere-se especialmente à utilização do referido fator de crescimento para tratar diferentes condições patológicas.
BR9908518-6A 1998-07-15 1999-03-05 Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios BR9908518A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
PCT/EP1999/001440 WO1999044629A2 (de) 1998-03-05 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Publications (1)

Publication Number Publication Date
BR9908518A true BR9908518A (pt) 2000-11-21

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908518-6A BR9908518A (pt) 1998-07-15 1999-03-05 Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios

Country Status (21)

Country Link
US (1) US6627200B1 (pt)
EP (1) EP1059931B1 (pt)
JP (1) JP2003521439A (pt)
KR (1) KR20010041624A (pt)
AT (1) ATE228371T1 (pt)
AU (1) AU747063B2 (pt)
BR (1) BR9908518A (pt)
CA (1) CA2322684A1 (pt)
CZ (1) CZ20003238A3 (pt)
DE (1) DE59903541D1 (pt)
DK (1) DK1059931T3 (pt)
EE (1) EE200000510A (pt)
ES (1) ES2188140T3 (pt)
HU (1) HUP0102046A3 (pt)
IS (1) IS1986B (pt)
NO (1) NO20004393L (pt)
NZ (1) NZ506695A (pt)
PL (1) PL343427A1 (pt)
PT (1) PT1059931E (pt)
SI (1) SI1059931T1 (pt)
WO (1) WO1999044629A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031474A2 (en) * 2001-10-04 2003-04-17 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
AU2003290059A1 (en) * 2002-12-16 2004-07-09 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
CA2429027C (en) * 1993-09-16 2011-04-05 Indiana University Foundation Antibodies against human receptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 Martin Lotz Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
NZ506695A (en) 2005-01-28
IS5613A (is) 2000-08-30
EE200000510A (et) 2002-02-15
HUP0102046A3 (en) 2006-02-28
ATE228371T1 (de) 2002-12-15
DE59903541D1 (de) 2003-01-09
AU747063B2 (en) 2002-05-09
ES2188140T3 (es) 2003-06-16
EP1059931B1 (de) 2002-11-27
EP1059931A2 (de) 2000-12-20
SI1059931T1 (en) 2003-04-30
WO1999044629A3 (de) 2000-01-06
JP2003521439A (ja) 2003-07-15
WO1999044629A2 (de) 1999-09-10
CZ20003238A3 (cs) 2001-10-17
HUP0102046A2 (hu) 2001-10-28
NO20004393L (no) 2000-10-31
NO20004393D0 (no) 2000-09-04
IS1986B (is) 2005-02-15
AU2932499A (en) 1999-09-20
KR20010041624A (ko) 2001-05-25
PT1059931E (pt) 2003-04-30
PL343427A1 (en) 2001-08-13
DK1059931T3 (da) 2003-03-24
US6627200B1 (en) 2003-09-30
CA2322684A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
DE69326937D1 (de) Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DK0910647T3 (da) Human DNase i hyperaktive varianter
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BRPI0409926A (pt) saposina c-dops: um agente antitumor
BR9908518A (pt) Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
ATE297464T1 (de) Pharmazeutische zusammensetzungen zur therapie der herzinsuffizienz
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
NZ332586A (en) Suppression of endogenous gene and replacement of suppressed gene sequence

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1999 DE 28/04/2009.